Insights on FRTX

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 9.0K → 7.94M (in $), with an average increase of 91.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.10M → -1.23M (in $), with an average decrease of 158.8% per quarter

Highlights

Market Capitalization
5.4M
Book Value
$1.66
Earnings Per Share (EPS)
-1.06
Wall Street Target Price
4.5
Profit Margin
-71.12%
Operating Margin TTM
-79.44%
Return On Assets TTM
-36.37%
Return On Equity TTM
-66.5%
Revenue TTM
8.0M
Revenue Per Share TTM
1.48
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-27.8M
EBITDA
-6.3M
Diluted Eps TTM
-1.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

FAQs